TN2011000437A1 - Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof - Google Patents

Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

Info

Publication number
TN2011000437A1
TN2011000437A1 TN2011000437A TN2011000437A TN2011000437A1 TN 2011000437 A1 TN2011000437 A1 TN 2011000437A1 TN 2011000437 A TN2011000437 A TN 2011000437A TN 2011000437 A TN2011000437 A TN 2011000437A TN 2011000437 A1 TN2011000437 A1 TN 2011000437A1
Authority
TN
Tunisia
Prior art keywords
pharmaceutical compositions
methods
receptor
human glp
substituted azoanthracene
Prior art date
Application number
TN2011000437A
Other languages
English (en)
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of TN2011000437A1 publication Critical patent/TN2011000437A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Secondary Cells (AREA)
TN2011000437A 2009-03-30 2011-08-25 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof TN2011000437A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16452309P 2009-03-30 2009-03-30
US30934810P 2010-03-01 2010-03-01
PCT/US2010/029172 WO2010114824A1 (fr) 2009-03-30 2010-03-30 Dérivés d'azoanthracène substitués, compositions pharmaceutiques et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
TN2011000437A1 true TN2011000437A1 (en) 2013-03-27

Family

ID=42828657

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000437A TN2011000437A1 (en) 2009-03-30 2011-08-25 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

Country Status (18)

Country Link
US (3) US8383644B2 (fr)
EP (1) EP2413693B1 (fr)
JP (1) JP5755217B2 (fr)
KR (1) KR101732978B1 (fr)
CN (1) CN102378574B (fr)
AU (1) AU2010232750B2 (fr)
BR (1) BRPI1013579A2 (fr)
CA (1) CA2757084C (fr)
DK (1) DK2413693T3 (fr)
EA (1) EA023430B1 (fr)
ES (1) ES2553645T3 (fr)
HK (1) HK1164050A1 (fr)
IL (1) IL214822A (fr)
MA (1) MA33219B1 (fr)
MX (1) MX2011010347A (fr)
SG (1) SG174205A1 (fr)
TN (1) TN2011000437A1 (fr)
WO (1) WO2010114824A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA023430B1 (ru) 2009-03-30 2016-06-30 виТиви ТЕРАПЬЮТИКС ЭлЭлСи Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
EP2768799B1 (fr) 2011-10-17 2019-08-07 Biotheryx Inc. Biaryle alkyle amides substitués
CN104968341B (zh) * 2013-01-17 2020-06-09 Vtv治疗有限责任公司 Glp1r激动剂和二甲双胍的组合及其在制备治疗2型糖尿病和其他障碍的药物中的用途
EP3185860A4 (fr) 2014-08-29 2018-08-29 The Board of Regents of the University of Texas System Nouveaux analogues de la capsazépine pour le traitement du cancer et d'autres maladies prolifératives
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
KR20210005843A (ko) * 2018-05-08 2021-01-15 브이티브이 테라퓨틱스 엘엘씨 Glp1r 작용제의 치료적 용도
TWI707683B (zh) * 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Ｇｌｐ－１受體促效劑及其用途
CN115315426B (zh) * 2020-04-01 2023-12-12 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
WO2021196949A1 (fr) 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Forme cristalline a d'antagoniste du récepteur glp-1 et son procédé de préparation
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
EP4159719A1 (fr) * 2020-05-28 2023-04-05 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Procédé de préparation de sel de diacide de propanoate de méthyle (s)-2-amino-3-(4-(2,3-diméthylpyridine-4-yl)phényl)
WO2021242806A1 (fr) 2020-05-28 2021-12-02 Vtv Therapeutics Llc Intermédiaires et procédés de préparation d'un agoniste du récepteur glp-1
EP4159722A4 (fr) 2020-05-28 2024-06-26 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Procédé de préparation d'agoniste du récepteur glp-1
TW202206412A (zh) 2020-05-28 2022-02-16 美商維特衛治療有限責任公司 製備（ｓ）－２－胺基－３－（４－（２，３－二甲基吡啶－４－基）苯基）丙酸甲酯及其鹽酸鹽的方法
CN115697968B (zh) * 2020-05-28 2024-03-29 杭州中美华东制药有限公司 (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法
US20230348484A1 (en) 2020-05-28 2023-11-02 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Method for preparing glp-1 receptor agonist free base
AU2021306414A1 (en) 2020-09-01 2023-05-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused imidazole derivative, preparation method therefor, and medical use thereof
TW202227455A (zh) * 2020-09-21 2022-07-16 美商維特衛治療有限責任公司 異喹啉衍生物的無定形形式
CA3194283A1 (fr) * 2020-10-08 2022-04-14 Eli Lilly And Company Composes de 6-methoxy-3,4-dihydro-1h-isoquinoline utiles dans le traitement du diabete
WO2022078152A1 (fr) 2020-10-12 2022-04-21 杭州中美华东制药有限公司 Agoniste du récepteur de glp-1, la benzimidazolone et son utilisation
CA3200245A1 (fr) 2020-11-27 2022-06-02 Junjun Wu Derive de benzimidazole, son procede de preparation et son utilisation medicale
CN116940561A (zh) 2021-03-22 2023-10-24 杭州中美华东制药有限公司 噻吩类glp-1受体激动剂及其用途
EP4317145A1 (fr) 2021-03-24 2024-02-07 Shionogi & Co., Ltd Composition pharmaceutique contenant un agoniste du récepteur glp-1 comportant un cycle fusionné
CN117500808A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
WO2022262143A1 (fr) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 Procédé de préparation de borate de pyridine
EP4361145A1 (fr) 2021-06-24 2024-05-01 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Agoniste de récepteurs de glp-1 et composition et utilisation associées
WO2023029979A1 (fr) * 2021-09-03 2023-03-09 杭州中美华东制药有限公司 Procédé de préparation d'un intermédiaire agoniste du récepteur de glp-1
CA3231153A1 (fr) 2021-09-08 2023-03-16 Kosuke Takemoto Medicament destine a la prevention et au traitement de maladies liees a l'activite anti-obesite
CA3233453A1 (fr) 2021-09-28 2023-04-06 Meimei Chen Composition solide d'agoniste du recepteur glp-1

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795265A (fr) * 1972-02-09 1973-08-09 Philips Nv Nouveaux derives de quinoleine a activite pharmacologique
EP0233728A1 (fr) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. Dérivés de 1,4-benzoxazine, leur préparation et leur application
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
WO2000042026A1 (fr) * 1999-01-15 2000-07-20 Novo Nordisk A/S Agonistes non peptidiques de glp-1
IL157093A0 (en) 2001-03-27 2004-02-08 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
US6933303B2 (en) * 2001-10-19 2005-08-23 Transtech Pharma, Inc. Heteroaryl-fused nitrogen heterocycles as therapeutic agents
WO2003055482A1 (fr) 2001-12-21 2003-07-10 Novo Nordisk A/S Derives amide utiles en tant qu'activateurs de la glucokinase
KR20050114242A (ko) * 2003-03-26 2005-12-05 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서 이용되는테트라하이드로이소퀴놀릴 아세트아마이드 유도체
US7501538B2 (en) * 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
WO2008118935A1 (fr) * 2007-03-26 2008-10-02 Neurogen Corporation Composés et procédés de préparation d'aminométhyl-2,3,8,9-tétrahydro-7h-1,4-dioxino[2,3-e]indol-8-ones substitués
AU2009221722B2 (en) 2008-03-07 2014-12-18 Vtv Therapeutics Llc Oxadiazoanthracene compounds for the treatment of diabetes
WO2009126709A1 (fr) 2008-04-09 2009-10-15 Transtech Pharma, Inc. Ligands pour le récepteur de glp-1 et procédés de découverte de ceux-ci
EA023430B1 (ru) 2009-03-30 2016-06-30 виТиви ТЕРАПЬЮТИКС ЭлЭлСи Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
EP2579888A2 (fr) 2010-06-09 2013-04-17 Receptos, Inc. Nouveaux stabilisants et modulateurs de récepteur glp-1

Also Published As

Publication number Publication date
MA33219B1 (fr) 2012-04-02
KR101732978B1 (ko) 2017-05-08
IL214822A0 (en) 2011-11-30
US20110160198A1 (en) 2011-06-30
EA201171197A8 (ru) 2014-10-30
MX2011010347A (es) 2011-11-29
EP2413693B1 (fr) 2015-09-09
EP2413693A1 (fr) 2012-02-08
IL214822A (en) 2016-08-31
EA023430B1 (ru) 2016-06-30
BRPI1013579A2 (pt) 2020-11-03
WO2010114824A1 (fr) 2010-10-07
AU2010232750A1 (en) 2011-09-08
US20130096150A1 (en) 2013-04-18
CA2757084C (fr) 2017-08-29
CA2757084A1 (fr) 2010-10-07
US8987295B2 (en) 2015-03-24
EP2413693A4 (fr) 2012-08-22
ES2553645T3 (es) 2015-12-10
DK2413693T3 (en) 2015-11-16
CN102378574B (zh) 2013-11-20
JP2012522060A (ja) 2012-09-20
CN102378574A (zh) 2012-03-14
WO2010114824A8 (fr) 2011-10-06
US9175003B2 (en) 2015-11-03
KR20120006506A (ko) 2012-01-18
JP5755217B2 (ja) 2015-07-29
HK1164050A1 (en) 2012-09-21
EA201171197A1 (ru) 2012-04-30
AU2010232750B2 (en) 2015-10-29
US8383644B2 (en) 2013-02-26
US20150148539A1 (en) 2015-05-28
SG174205A1 (en) 2011-10-28

Similar Documents

Publication Publication Date Title
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
HK1154587A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
EP2582676A4 (fr) Modulateurs allostériques positifs du récepteur m1 de l'amide tétrahydroquinoline
WO2015157559A3 (fr) Saxitoxines 10',11'-modifiées pour le traitement de la douleur
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
EP2037739A4 (fr) Effecteurs allostériques positifs du récepteur m1 à base de quinolone à substitution benzyle
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
MX2013002119A (es) Sustituidas-2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas como moduladores de kcnq2/3.
WO2009134668A3 (fr) Modulateurs allostériques positifs pour le récepteur m1 de 4-oxo-1,4-dihydroquinoléine
IL206738A0 (en) Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
WO2009117283A3 (fr) Modulateurs allostériques positifs du récepteur m1 de la quinolizidine
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.